ResearcherBaylor College of MedicineNo recent work listed
Ethan C. Poteet
Matched on OpenAlex author ID A5081352529. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper
Papers 2
- Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib. Co-author DOI 10.1371/journal.pone.0213294↗
- Overexpression of Semaphorin-3E enhances pancreatic cancer cell growth and associates with poor patient survival. Co-author DOI 10.18632/oncotarget.13704↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Qizhi Cathy Yao · 2 shared papers, 2016–2019 · strength 0.17
- Paper Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment … DOI 10.1371/journal.pone.0213294↗
- Paper Overexpression of Semaphorin-3E enhances pancreatic cancer cell growth and associates with poor patient survival. DOI 10.18632/oncotarget.13704↗
- Changyi Chen · 2 shared papers, 2016–2019 · strength 0.17
- Paper Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment … DOI 10.1371/journal.pone.0213294↗
- Paper Overexpression of Semaphorin-3E enhances pancreatic cancer cell growth and associates with poor patient survival. DOI 10.18632/oncotarget.13704↗
- George Van Buren · 2 shared papers, 2016–2019 · strength 0.17
- Paper Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment … DOI 10.1371/journal.pone.0213294↗
- Paper Overexpression of Semaphorin-3E enhances pancreatic cancer cell growth and associates with poor patient survival. DOI 10.18632/oncotarget.13704↗
- Dongliang Liu · 1 shared paper, 2019 · strength 0.11
- Lin-Kin Yong · 1 shared paper, 2016 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.